Navigation Links
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Date:5/8/2008

welcome additions to the treatment options currently available for improving patient care."

Schering-Plough acquired asenapine in November 2007 through its combination with Organon BioSciences, which developed the investigational antipsychotic agent. The Food and Drug Administration is reviewing a new drug application (NDA) for asenapine in the treatment for schizophrenia and acute manic or mixed episodes associated with bipolar I disorder. The asenapine Olympia clinical trial program thus far has involved over 3,000 patients and has included bipolar mania and acute schizophrenia trials.

"Based on results from the Olympia trial program, we believe asenapine has the potential to address a clinically important unmet need for patients with schizophrenia and bipolar disorder," said Robert J. Spiegel, M.D., Chief Medical Officer and Senior Vice President, Schering-Plough Research Institute.

Olympia Data: Bipolar I Disorder

The bipolar I disorder program includes two placebo- and active-controlled, three-week trials followed by an extension study totaling one year of treatment involving nearly 1,000 patients with bipolar I disorder. Treatment response was measured using the Young Mania Rating Scale (YMRS) score, an 11-item scale used to evaluate manic symptoms.

In the trials, both asenapine and the active-control drug olanzapine* produced greater mean reductions in YMRS total scores versus placebo after three weeks of treatment. Asenapine produced 13- and 14-point reductions in the YMRS total score from baseline to day 21 (P<0.05 versus placebo; olanzapine was also demonstrated to be statistically superior to placebo; there was no direct comparison between asenapine and olanzapine). In a 9-week extension of the 3-week trials, asenapine was found to be noninferior to olanzapine on the primary efficacy measure, change in YMRS.

The overall incidence of treatment-related adverse events (AEs) in the trials was 60.8 percent in the asena
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- Research and Markets  ( http://www.researchandmarkets.com/research/rf4hfn/global ) has ... Diseases Market 2015-2019" report to their offering. ... grow at a CAGR of 4.77% over the ... present scenario and the growth prospects of the ... To calculate the market size, the report considers ...
(Date:6/3/2015)... BOSTON , June 3, 2015 PillPack, ... has completed a $50 million round of financing led ... Menlo Ventures, and Sherpa Ventures. The capital will be ... world-class team, and build retail pharmacies in US markets. ... and launched a better, simpler pharmacy experience that folks ...
(Date:6/3/2015)... June 3, 2015  Armetheon, Inc., a specialty ... cardiovascular diseases, today announced that Sanjay Kakkar ... Executive Officer, effective immediately. Dr. Kakkar brings more ... enterprises, with a successful track record in advancing ... With expertise that includes the development of novel ...
Breaking Medicine Technology:Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4
... 2007--Treatment data from,Synovate Healthcare’s European Oncology Monitor reveals ... could become eligible,for a breast cancer treatment showing ... subject of a recent study detailed,in the online ... rates were shown in patients who had switched ...
... Findings Show Survival Improvement with Lower Doses ... and other,Drugs in Newly Diagnosed Myeloma -, ... -- The,International Myeloma Foundation (IMF) - supporting ... myeloma patients,families, researchers and physicians - today ...
Cached Medicine Technology:Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 2Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 3The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients 2The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients 3
(Date:6/3/2015)... Loma Linda University Health and Adventist Health ... Memorial Hospital (SGMH). The SGMH board voted unanimously to ... “Loma Linda University Health has been serving the Pass ... officer, Loma Linda University Medical Center. “We are thrilled ... this community.” , Under the proposed affiliation, Loma ...
(Date:6/3/2015)... “ Harmony ” was featured on NewsWatch as part ... latest and coolest applications on the market for iOS, Android, ... expert, conducted the app review and shared with viewers how ... aspect of their life. , A common mistake people make ... in their life. However, hypnotherapy is intended for anyone who ...
(Date:6/3/2015)... BC (PRWEB) June 03, 2015 Vancouver ... announced that the firm will now handle personal injury ... Greater Vancouver on the rise, more and more people ... year bus accidents cause needless suffering, serious injury and ... a result of a bus accident in BC you ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
Breaking Medicine News(10 mins):Health News:Loma Linda University Health and Adventist Health Enter into Exclusive Affiliation Negotiations with San Gorgonio Memorial Hospital 2Health News:An Application to Enjoy Hypnotherapy Sessions at Home was featured on NewsWatch Television 2Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3
... Alan Mozes HealthDay Reporter , TUESDAY, May 15 ... silver bullet when it comes to symptom relief for acute ... of six prior studies found that the sprays confer only ... for three weeks at relatively high doses. The disappointing ...
... May 15 (HealthDay News) -- Should Americans be able to buy ... they,re infected with the virus that causes AIDS? , , A ... question Tuesday, and the answer the panel arrives at could pave ... advisory panel recommendations are not binding, but they are often followed ...
... KNOX, Ky., May 15, 2012 The U.S. Army Medical ... to Mastership in the American College of Physicians (MACP). Only ... eminence through their contributions to the field of internal medicine ... or volunteerism, were awarded a Mastership in 2012. One of ...
... Child,s Age and Severity of Gait Abnormality ,Most ... 2. And while some toe walkingwhere a child primarily walks ... the heel to the groundis common, persistent toe walking beyond ... article, "Idiopathic Toe Walking," outlines the appropriate steps for effectively ...
... Center at HakensackUMC, one of the nation,s top 50 cancer ... year,s program, titled New Horizons in Neuro-Oncology- Innovations in the ... the most important advancements and innovations for the treatment of ... on Friday, May 18 from 8:00am to 1:00pm. ...
... a way to save money while having little effect on ... study. Researchers say that 57.6 percent of patients ... schizophrenia or bipolar disorder, the conditions for which the drugs ... is not FDA-approved is called off-label use. "Given ...
Cached Medicine News:Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 2Health News:Steroid Nasal Sprays Show Small Benefit for Sinusitis: Study 3Health News:FDA Panel to Consider At-Home HIV Test 2Health News:FDA Panel to Consider At-Home HIV Test 3Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 2Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 3Health News:US Army internal medicine Masters, Fellows honored by American College of Physicians 4Health News:Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights 2Health News:John Theurer Cancer Center hosting 8th Annual Neuro-Oncology Symposium 2Health News:Reducing off-label use of antipsychotic medications may save money 2Health News:Reducing off-label use of antipsychotic medications may save money 3
These backbiters enable simple access to the anterior horn of the meniscus....
ACUFEX Loop Handle. Blunt nose basket punch enables flush contouring of meniscus....
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: